Skip to main content
. 2018 Feb 27;9(3):326. doi: 10.1038/s41419-018-0347-x

Fig. 1. SMYD2 is highly expressed in triple-negative breast cancers.

Fig. 1

a The expression profiles of SMYD2 were analyzed in cross-cancer alteration from 91 studies with cBio Cancer Genomics Portal. SMYD2 was upregulated in all types of cancers, particularly in breast cancers. b Western blot analysis of SMYD2 expression from whole cell lysates, cytoplasmic fraction and nuclear fraction in human breast cancer cells as well as in non-tumorigenic MCF10A mammary epithelial cells. c Immunofluorescence staining of SMYD2 in human breast cancer cells as well as in MCF10A cells. d and e The upregulation of SMYD2 was found in all subtypes of breast cancers and was highly related to poor survival